Insulin Glargine v Rosiglitazone as add-on Therapy in Patients Failing Sulfonylurea and Metformin Combination Therapy

Completed · Phase 4

Conditions studied: Type 2 Diabetes Mellitus

In brief

To compare the glycemic control, as measured by HbA1C, between insulin glargine and rosiglitazone add-on therapies in patients who fail oral combination of a sulfonylurea and metformin

Key facts

Study ID

NCT00358124

Run by

Sanofi

People needed

220

Starts

2001-01-01

Expected to finish

2002-06-01

Last updated by the study team

2011-01-11

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of type 2 diabetes mellitus for at least one year;
• Continuous treatment with at least half maximally labeled dose of a sulfonylurea and at least 1000 mg metformin daily for at least three months ;
• Glycated hemoglobin between 7.5 and 11 % units, inclusive;
• Willingness to accept, and ability to inject insulin glargine therapy

You may not qualify if…

• Stroke, MI, coronary artery bypass graft, percutaneous transluminal coronary angioplasty or angina pectoris within the last 12 months;
• Congestive heart failure requiring pharmacological treatment;
• Serum creatinine > 1.5 mg/dl for males, or > 1.4 mg/dl for females;
• Acute or chronic metabolic acidosis, including diabetic ketoacidosis;
• Planned radiological examinations requiring administration of contrasting agents;
• Clinical evidence of active liver disease, or serum ALT 2.5 times the upper limit of the normal range;
• History of hypoglycemia unawareness;
• Pregnancy or lactation;
• Failure to use adequate contraception (women of current reproductive potential only);
• Known hypersensitivity to insulin glargine, rosiglitazone or any of the components of insulin glargine rosiglitazone;
• BMI >25 kg/m2;
• Malignancy except basal cell carcinoma within the last five years;
• History of substance or alcohol abuse within last two years, or current addiction to substance or alcohol abuse;
• Any disease or condition that in the opinion of the investigator and/or sponsor may interfere with completion of the study;
• Incapability to comply with study procedures

Where it is running

• Sanofi-Aventis — Bridgewater, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.